• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    EVOQUE Tricuspid Valve Launch Might Change The Case For Investing In Edwards Lifesciences (EW)

    Simply Wall St·08/22/2026 02:28:11
    Listen to the news
    • Edwards Lifesciences recently held its annual Asia Pacific Patient Experience event on structural heart disease and highlighted its pipeline, including advancing transcatheter aortic, mitral, and tricuspid valve therapies that are expected to benefit from evolving treatment guidelines and policy updates.
    • A central development is the planned 2024 launch of the EVOQUE transcatheter tricuspid valve, which could make Edwards the first mover in this therapy area and reinforce its position across the broader structural heart market.
    • Next, we’ll examine how the anticipated EVOQUE tricuspid valve launch could reshape Edwards Lifesciences’ long‑term investment narrative and growth profile.

    The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    Edwards Lifesciences Investment Narrative Recap

    To own Edwards Lifesciences, you need to believe in long term demand for minimally invasive structural heart therapies and the company’s ability to convert its pipeline into durable revenue and earnings. The Asia Pacific Patient Experience event reinforces that story but does not materially change the key near term swing factors, which still look centered on early TAVR indication approvals as a positive catalyst and tariff impacts as a meaningful earnings risk.

    The most directly relevant development is the anticipated 2024 launch of the EVOQUE transcatheter tricuspid valve, which aligns with Edwards’ focus on underpenetrated structural heart niches. If EVOQUE successfully broadens the treated tricuspid population, it could support the multiyear growth case that underpins many valuation models, while sitting alongside early TAVR indications as a second important product driven catalyst.

    However, investors should also be aware that rising tariff related costs could pressure margins and earnings just as expectations around...

    Read the full narrative on Edwards Lifesciences (it's free!)

    Edwards Lifesciences' narrative projects $8.5 billion revenue and $2.2 billion earnings by 2029. This requires 9.3% yearly revenue growth and an earnings increase of about $1.2 billion from $979.9 million today.

    Uncover how Edwards Lifesciences' forecasts yield a $100.96 fair value, a 12% upside to its current price.

    Exploring Other Perspectives

    EW 1-Year Stock Price Chart
    EW 1-Year Stock Price Chart

    Three members of the Simply Wall St Community currently see Edwards’ fair value between US$92.19 and US$100.96, reflecting a tight but varied set of assumptions. Against that backdrop, the potential for earlier TAVR indications to expand the treatable patient pool is a key factor that could influence how these different views on the company’s future performance play out, so it is worth comparing several of these perspectives side by side.

    Explore 3 other fair value estimates on Edwards Lifesciences - why the stock might be worth as much as 12% more than the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Want Some Alternatives?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.